Edward N. Libby

7.2k citations

87 papers · 2.5k indexed · 1 hit paper · h-index 22

Impact in

Hematology top 0.5%
- Multiple Myeloma Research and Treatments
Internal Medicine top 2%
- Venous Thromboembolism Diagnosis and Management

Papers in

Hematology 46
- Multiple Myeloma Research and Treatments 40
Internal Medicine 13
- Venous Thromboembolism Diagnosis and Management 13

Co-authors: David García Andrew J. Cowan Damian J. Green Ajay K. Gopal David G. Coffey Mark Crowther Sherilyn A. Tuazon Leona Holmberg
Journals: Blood (27 papers)Journal of Clinical Oncology (9 papers)British Journal of Haematology (4 papers)The Lancet Oncology (3 papers)Biology of Blood and Marrow Transplantation (3 papers)
Partner nations: United States Canada South Africa

In The Last Decade

Edward N. Libby

84 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Diagnosis and Management of Multiple Myeloma 2022 · 526 citations

Peers

Countries citing papers authored by Edward N. Libby

Since Specialization

Citations

This map shows the geographic impact of Edward N. Libby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward N. Libby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward N. Libby more than expected).

Fields of papers citing papers by Edward N. Libby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward N. Libby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward N. Libby. The network helps show where Edward N. Libby may publish in the future.

Co-authors

The 25 scholars most cited alongside Edward N. Libby, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Edward N. Libby Line = papers co-authored together Edward N. Libby links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Jesús G. Berdeja, Min Yang, Noopur Raje, Edward N. Libby, Simon S. Jones, Nicole Birrer, David Tamang, Peter M. Voorhees, Andrew J. Yee, Robert J Markelewicz, Jeffrey G. Supko, William Bensinger, Jill N. Burke, Ellen Wallace, Paul G. Richardson, Catherine Wheeler	2024	0
2	γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial The Lancet Oncology ·Andrew J. Cowan, Margot J. Pont, Blythe Sather, Cameron J. Turtle, Brian G. Till, Edward N. Libby, David G. Coffey, Sherilyn A. Tuazon, Brent L. Wood, Ted Gooley, 益三長野, Jenna Voutsinas, Xiaoling Song, Mazyar Shadman, Jordan Gauthier, Aude G. Chapuis, Filippo Milano, David G. Maloney, Stanley R. Riddell, Damian J. Green	2023	52
3	P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES HemaSphere ·Morie A. Gertz, Adam D. Cohen, Raymond L. Comenzo, Efstathios Kastritis, Heather Landau, Edward N. Libby, Michaela Liedtke, Vaishali Sanchorawala, Stefan Schönland, Ashutosh Wechalekar, Yukio Ando, Youngil Koh, Jeffrey A. Zonder, Giovanni Palladini, Kawthar Ayoub Asaad, Carol L. Karp, 元江, Anne Conrad, Gene G. Kinney, Giampaolo Merlini	2023	1
4	Radiographic Response of Solitary Plasmacytomas After Conformal Radiotherapy May Be Delayed American Journal of Clinical Oncology ·Jorge M. Correia-Pinto, Martha C. Forejt, Edward N. Libby, Andrew J. Cowan, Mary Kwok, Sarah S. Lee, Damian J. Green, David G. Coffey, Leona Holmberg, Delphine L. Chen, Yolanda D. Tseng	2022	1
5	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study The Lancet Haematology ·Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R. Shustov, Brian G. Till, Chaitra S. Ujjani, Edward N. Libby, Mary Philip, Julien Cohier, M. M. Boltinescu, Guenther Dahlhofff, Karolyn Morris, Heather Rasmussen, Fatemeh Behnia, Jenna Voutsinas, Ajay K. Gopal	2021	33
6	Assessment of Left Ventricular, Right Ventricular, and Left Atrial Strain in Light-Chain Amyloidosis JACC CardioOncology ·Douglas Leedy, Alexi Vasbinder, Hans Huang, 均史岩崎, Andrew J. Cowan, Ajay K. Gopal, James N. Kirkpatrick, Edward N. Libby, Richard K. Cheng	2020	3
7	Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Blood Cancer Journal ·Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Axel Hoos, Ira Gupta, Véronique Bragulat, Zangdong He, Joanna Opalinska, Adam D. Cohen	2019	171
8	Global burden of multiple myeloma: A systematic analysis for the Global Burden of Disease study 2016. Journal of Clinical Oncology ·Andrew J. Cowan, Edward N. Libby, Christina Fitzmaurice	2018	61
9	Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial The Lancet Oncology ·Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat, Peter M. Voorhees, Brandi Reeves, Edward N. Libby, Paul G. Richardson, Larry D. Anderson, Heather J. Sutherland, Kwee Yong, Axel Hoos, M Gorczyca, Soumi Lahiri, Zangdong He, Daren Austin, Joanna Opalinska, Adam D. Cohen	2018	192
10	Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy Biology of Blood and Marrow Transplantation ·Andrew J. Cowan, Philip A. Stevenson, Edward N. Libby, Pamela S. Becker, David G. Coffey, Damian J. Green, Teresa S. Hyun, Jonathan R. Fromm, Ajay K. Gopal, Leona Holmberg	2018	19
11	Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial Blood ·Ryan D. Cassaday, Jonathan R. Fromm, Andrew J. Cowan, Stephen D. Smith, Edward N. Libby, Mary Philip, 良平茂木, Rahim َAhmadi, Sandra Kanan, Fatemeh Behnia, Ajay K. Gopal	2017	9
12	Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma Annals of Oncology ·Solomon A. Graf, Philip A. Stevenson, Leona Holmberg, Brian G. Till, Oliver W. Press, Thomas R. Chauncey, Stephen D. Smith, Mary Philip, Johnnie J. Orozco, Andrei R. Shustov, 费振华, Edward N. Libby, Jack W. Singer, John M. Pagel, David G. Maloney, Yi Zhou, Ryan D. Cassaday, Ajay K. Gopal	2015	20
13	Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy Bone Marrow Transplantation ·Radinas Putri Ayuning Firdaus, Michael Linenberger, Leona Holmberg, Mingliang Bai, Pamela S. Becker, Laura Connelly‐Smith, Zandra Klippel, Nicholas Burwick, Ajay K. Gopal, Jack W. Singer, Edward N. Libby	2015	11
14	Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity Leukemia & lymphoma ·Colin Phipps, Ajay K. Gopal, Barry E. Storer, Ryan D. Cassaday, Oliver W. Press, Brian G. Till, John M. Pagel, Maria Corinna Palanca-Wessels, Mary Philip, William Bensinger, Leona Holmberg, Andrei R. Shustov, Damian J. Green, Thomas R. Chauncey, David G. Maloney, Edward N. Libby	2014	4
15	Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status Blood ·Maika Onishi, Leona Holmberg, Andrei R. Shustov, Xin Guan, S. Kusano, Mary Philip, Edward N. Libby, Ryan D. Cassaday, John M. Pagel, David G. Maloney, Damian J. Green, Brian G. Till, Oliver W. Press, Ajay K. Gopal	2013	2
16	Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia The American Journal of Medicine ·Charles L. Wiggins, Linda C. Harlan, Harold E. Nelson, Jennifer L. Stevens, Cheryl L. Willman, Edward N. Libby, Robert Hromas	2010	29
17	Tumor MET Expression May Not Predict the Risk of Venous Thromboembolism in Cancer Patients Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ·Hamid Sayar, Jekuk Chang, Thèrése Bocklage, Sang Joon Lee, Edward N. Libby, Ian Rabinowitz	2010	1
18	Rate of Thromboembolic Events in Mesothelioma The Annals of Thoracic Surgery ·A.C.de Castro Barbosa, Sang Joon Lee, Edward N. Libby, Claire F. Verschraegen	2008	12
19	False‐negative factor V Leiden genetic testing in a patient with recurrent deep venous thrombosis American Journal of Hematology ·Edward N. Libby, Jessica K. Booker, Margaret L. Gulley, David García, Stephan Moll	2006	7
20	Cranial Pseudotumour in Haemophilia Haemophilia ·Edward N. Libby, G C White	2004	5

About Edward N. Libby

Edward N. Libby is a scholar working on Hematology, Internal Medicine, Oncology, Genetics and Pathology and Forensic Medicine, having authored 87 papers that have together received 2.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (40 papers), Lymphoma Diagnosis and Treatment (21 papers), Protein Degradation and Inhibitors (15 papers), Venous Thromboembolism Diagnosis and Management (13 papers), Viral-associated cancers and disorders (12 papers), Cancer Treatment and Pharmacology (11 papers), Chronic Lymphocytic Leukemia Research (8 papers) and CAR-T cell therapy research (8 papers). The work is most often cited by research in Hematology (1.2k citations), Internal Medicine (276 citations), Oncology (1.1k citations), Genetics (268 citations) and Pathology and Forensic Medicine (294 citations). Edward N. Libby has collaborated with scholars based in United States, Canada and South Africa. Frequent co-authors include David García, Andrew J. Cowan, Damian J. Green, Ajay K. Gopal, David G. Coffey, Mark Crowther, Sherilyn A. Tuazon, Leona Holmberg, Mary Kwok and Sarah Lee. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, The Lancet Oncology and Biology of Blood and Marrow Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact